Home›Trial›NCT05876377
NCT05876377Terminated

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

Study Summary

This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: * to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. * to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.

View on ClinicalTrials.gov ↗
Study Details
Enrollment1 participants
Primary Completion2026-05-31
Lead SponsorPfizer
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial was terminated before completion. Termination can indicate safety signals, futility findings, or business/regulatory decisions by the sponsor.

Primary completion: 2026-05-31
Enrolled: 1 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence